Title: Novel therapies for chronic myelogenous leukemia
Authors: Jahagirdar, B N ×
Miller, J S
Shet, A
Verfaillie, Catherine #
Issue Date: May-2001
Series Title: Experimental hematology vol:29 issue:5 pages:543-56
Abstract: The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation. We have systematically reviewed each of these novel therapeutic approaches in this article.
ISSN: 0301-472X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Interdepartemental Stem Cell Institute (-)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Jahagirdar BN, Exp Hematol. 2001.pdf Published 361KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science